General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Our Vision

Our Vision

When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.

Together, we help improve the lives of cancer patients

Novartis Oncology has achieved a transformational milestone in our mission to help improve the lives of cancer patients with the recent acquisition of the GSK oncology portfolio. More than a decade ago, Novartis AG was the first company to form a dedicated global business unit to develop and launch innovative oncology medicines that address the unmet medical needs of people with cancer and related diseases.

This acquisition expands the breadth and depth of our organization – over 10,000 oncology associates in 85 countries – to help deliver more therapies to more patients in their fight against cancer.

More than ever, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to helping improve the lives of cancer patients around the world. We now offer an unmatched portfolio of 22 oncology, hematology and rare disease medicines to treat more than 25 conditions worldwide. Our broad pipeline includes more than 25 new molecules in development, targeting key molecular pathways in cancer biology, including two AKT inhibitors acquired from GSK.

Read our fact sheet

Visit Novartis.com to learn more about our group of companies

Connecting within the oncology community

Making connections in science and building relationships with people in the oncology community fuels our ability to deliver innovative medicines for patients. The acquisition of the GSK oncology portfolio opens new potential for collaborations that may lead to the development of breakthrough therapies to transform patients’ lives.

Turning scientific possibility into clinical reality

More than a decade of success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. The acquisition of the GSK oncology portfolio enables us to serve healthcare professionals in a broader way, bring new solutions to more patients and explore the therapeutic potential of novel combinations that target multiple cancer pathways. Our strategy is composed of three elements:

Unique, dedicated global capabilities support our strategy.

At Novartis Oncology, we are a leader in driving the practice of precision oncology treatment. Learn about our viewpoint on achieving better patient outcomes.

"Together, we make innovation happen".